An Open-Label, Randomised, Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First or Second Line Treatment for Patients With HER2 Negative Locally Advanced or Metastatic Breast Cancer, or Loco-Regional Recurrence Not Amenable to Treatment by Surgery or Radiotherapy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
Most Recent Events
- 24 Jul 2018 Biomarkers information updated
- 19 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 19 Sep 2009 Actual initiation date (Aug 2009) added as reported by ClinicalTrials.gov.